Keros Therapeutics Inc Hematology Programs Investor Call Transcript
(technical difficulty) afternoon and welcome to the Keros Therapeutics ASH 2022 update call. (Operator Instructions)
As a reminder, this call will be recorded, and the link to the recording will be available on Keros's corporate website.
I would now like to introduce your host for today's program, Keith Regnante, the company's Chief Financial Officer.
Mr. Regnante, please go ahead.
Thank you, operator.
Thank you all for joining us on today's call. As we announced this morning, we are very excited to report clinical updates and preclinical data for our KER-050 and KER-047 hematology programs. The press release is available on our website at kerostx.com, and is also included as an exhibit in the Form 8-K that we filed with the Securities and Exchange Commission.
During this call, we'll be making a number of forward-looking statements. Please take a moment to review our disclaimer slide in the webcast, which notes that these forward-looking statements involve risks and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
